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ABSTRACT 
Objective: To statistically design, optimize and evaluate a liquid oral, floating in situ gel of metformin hydrochloride (MH) to increase the gastric 
residence time (the absorption window being the upper part of the duodenum), sustain and modulate the release behavior of the drug. No liquid 
oral SR formulations of MH are yet available in the market.  
Methods: A simple mixing based ionic cross-linking method was used for the formulation. A Two-square Factorial Design was employed and the 
effect of sodium alginate and three categorical levels of HPMC (K4M, K100M, E50) on the response variables were studied. 
Results: The optimized formulation gelled instantaneously in simulated gastric fluid and showed>24 h floating. The drug release in 1h was 37.98 %, 
followed by a moderate sustained release for 12 h. Pharmacodynamic studies showed a significant reduction in blood glucose levels in Wistar rats. 
Short term preclinical safety studies revealed no toxicity to pancreatic tissues. On the contrary, faster regeneration of the β cells of the islets of 
Langerhans was observed with the group treated with the optimized formulation. Stability studies revealed a 2-year shelf life. 
Conclusion: An elegant, needle-free, in situ gelling, SR liquid oral of metformin hydrochloride could be developed with drug release modulated as 
per official specifications for SR formulations of MH. This would be an interesting alternative for geriatric patients who find it difficult to swallow 
bulky tablets. 
Keywords: Liquid oral floating in situ gel, Metformin hydrochloride, Least square fit model, Pharmacodynamic study, Toxicity studies 




The successful design and optimization of effective drug delivery 
systems have become an integral part in improving various 
parameters such as the degree and rate at which the administered 
drug reaches the systemic circulation and research is continuously 
progressing in this area. Diseases like diabetes need much attention 
as glucose levels tend to increase after a meal and it should be 
maintained for the whole day for proper body activity. Metformin 
hydrochloride is an oral hypoglycemic agent and the first drug of 
choice to treat patients with Type II diabetes. It has an absolute oral 
bioavailability of 40% to 60%. It is highly hydrophilic with 
gastrointestinal absorption occurring mainly in the upper part of the 
intestine with peak plasma concentrations (Cmax
The tablet and capsule dosage forms have to be swallowed as a 
whole unit and in case of dosage adjustment, these cannot be broken 
into halves as they are designed for controlled release and the 
floating ability also depends on dimensions of the tablet. Elderly and 
dysphagic patients find it difficult to swallow bulky tablets and 
capsules. In such cases, high doses of the drug can be incorporated 
into liquid oral in situ gelling (ISG) formulations [1, 2]. Novel drug 
delivery systems like in situ gelling systems reduce adverse 
reactions, toxicity and frequency of dosing with improved efficacy, 
patient compliance and convenience [3-6]. In situ, gelling occurs due 
to one or a combination of different stimuli like pH changes, 
temperature modulation, solvent exchange and can be achieved in a 
gastric environment [7-9]. Various natural and synthetic polymers 
including polysaccharides like carrageenan, gellan gum, pectin and 
sodium alginate have been used in the development of in situ gelling 
systems which undergoes a phase transition in presence of various 
di and trivalent ions [10-12]. Sodium alginate is a natural and 
hydrophilic polymer suitable for the entrapment of water-soluble 
drugs [13-15], widely used in pharmaceutical formulations [16-18]. 
HPMC is used as a viscosity modifier. Sorbitol is used as a sweetener 
in liquid orals and studies have shown that gels containing 10-17 % 
sorbitol sustained the release of drug in rat stomach and a 
bioavailability of approximately 90% was achieved from orally 
administered syrups [19, 20]. 
) at 4.8 h. It has a 
short half-life of 1.5 to 4.5 h and therefore the development of gastro 
retentive systems of the drug would help sustain the drug release 
and improving oral bioavailability. When large doses of MH are 
needed, the frequency of dosing may be 2 to 3 times a day which 
may reduce patient compliance and therefore liquid oral sustained-
release (SR) formulations that give once a day dosing would be 
preferable. 
The current research work aimed at the development and evaluation 
of a floating, liquid oral dosage form of Metformin hydrochloride for 
sustained release, along with providing evidence regarding 
modulated drug release as per official specifications. No liquid oral 
sustained-release formulations of Metformin hydrochloride are 
available in market up to date and therefore an attempt is being to 
develop the same.  
MATERIALS AND METHODS 
Materials 
Metformin hydrochloride was procured from National 
Pharmaceuticals, Birgunj. Sodium alginate, pectin, calcium 
carbonate, HPMC (K4M, K100M, E50), sodium citrate, and sorbitol 
were obtained from Yarrow Chem Products, Mumbai. 
Methods 
Pre-formulation studies 
Drug-excipient compatibility studies by FT-IR 
To investigate any possible interaction between the drug and 
polymers used, the IR spectrum of the pure drug (MH) and the 
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binary mixture of drug and polymers was taken using FTIR (UV 
visible spectrophotometer, Alpha Bruker) [21-24].  
Design of experiment and statistical optimization 
The conventional methods of experimentation by changing one 
variable at a time being time-consuming, the Design of Experiment 
(DOE) was done using the JMP Statistical Software (Trial version 
13). The polymers and other quantities were selected based on 
reported literature on similar studies and initial screening 
experiments done to identify the optimum conditions and quantities 
required. Evaluation of preliminary batches was done based on 
responses such as in vitro gelling capacity, drug release and 
pourability (relative viscosity), to select the working concentration 
range of polymers (factors). The Two-Square Factorial design was 
used, taking two levels of the independent variable sodium alginate 
(Factor 1) coded at high and low levels and three categorical levels 
of HPMC (Factor 2) i.e., E50, K4M, K100M. 
Formulation of metformin HCl oral in situ gel by a simple 
mixing method 
Polymeric solutions of sodium alginate (0.7% and 1.25% w/v) with 
pectin (0.5% w/v) were prepared by adding it to ultrapure water 
containing sodium citrate (0.25% w/v) and calcium carbonate (1% 
w/v). This solution was then heated to 60○C with continuous 
stirring. After cooling to below 40○
Evaluation 
C, HPMC (0.5% w/v) was added, 
followed by 500 mg of MH/5 ml, sorbitol (10% w/v) and sodium 
benzoate (0.1% w/v). Ultra-pure water was used as a solvent [25-
27]. A batch minimum of 100 ml was prepared. 
pH of the gel 
The pH of the formulation was determined using a calibrated pH 
meter and readings taken in triplicate [28-29]. 
Determination of in vitro gelation time and floating behavior 
In vitro gelation time was determined by placing the sols in an open 
vial tied to the paddle in the USP Type II Dissolution apparatus 
(Paddle type) containing 900 ml of SGF (0.1 mol L–1HCl, pH 1.2) at 
37±0.5○
Viscosity  
C. The buoyancy lag time and duration of floating was noted. 
The readings were taken in triplicate [30-33]. 
The viscosity of the sol and gel in 0.1N HCl was determined using 
Brookfield viscometer (DV-II+Pro LV model). The selected 
formulations (250 ml) were poured into the sample adaptor of the 
viscometer and the viscosity measured at room temperature using 
SC4-18 spindle for the sols and LV2 spindle for the gels. The angular 
velocity was gradually increased from 10 to 50 rpm with a 6 sec wait 
period, the hierarchy reversed and the average taken. The viscosity 
measurements were made in triplicate [34].  
In vitro drug release and kinetics 
The drug release study was carried out using USP Type II dissolution 
apparatus (Paddle type, Electrolab). 5 ml of the formulation was 
kept in vials and dissolution done. At predetermined time intervals, 
5 ml of sample solution was withdrawn, filtered through a 0.45 μm 
membrane filter, suitably diluted and analyzed by UV 
spectrophotometrically at 232 nm. The same amount of fresh 
dissolution medium was replaced immediately after withdrawal of 
the test sample [35-37]. The mechanism of drug release was studied 
by fitting the dissolution data in the zero-order, first-order, Higuchi 
model, Korsemeyer-Peppas equation following model-dependent 
kinetics. Based on the slope and r2
Optimization 
 values obtained, the mechanism 
of drug release was determined [38-41]. 
The values obtained after evaluating the responses experimentally 
were fed into the JMP software and the data analyzed. The numerical 
optimization techniques and the least square fit model was 
employed. The desirability approach (using Prediction profiler) was 
used to generate the optimum settings for the formulation. 
Optimization was done for the responses by keeping in vitro gelation 
and drug release at 1h at maximum while that at 8 h and 12 h were 
kept in the range [42]. The optimization target and constraints were 
set based on the official IP specifications. 
In vivo pharmacodynamic study 
The animal studies were done according to the protocol approved by 
the Institutional Animal Ethics Committee formed under the CPSCEA 
guidelines (CPSEA Registration No: 1564/PO/a/11/CPSEA-23-11-
2012). Wistar rats weighing between 150-250 g were divided into 3 
groups, each with six rats. They were acclimatized for a week prior 
to the experiment, caged in a fully ventilated room at a temperature of 
25±2○
Statistical analysis 
C, with a 12 h light/dark cycle with free access to standard chow 
diet and water. These have fasted for 24h and diabetes-induced with 
Streptozotocin 40 mg/kg (i. v). Treatment was started once the rat 
became diabetic. Group-1(control) was treated with physiological 
saline), Group-2 with the pure drug solution (0.116 ml) of MH (58.31 
mg/kg dose) and Group-3 was given the optimized liquid oral (0.116 
ml) of MH (58.31 mg/kg dose). Comparison was done between the 
groups to identify any significant differences [43-45]. 
Statistical analysis was carried out using the ANOVA and p-values 
less than 0.05 were considered statistically significant. 
Toxicity (Histopathological) studies 
At the end of the animal study, the rats were fasted overnight, 
anesthetized with Ketamine (80 mg/kg) and Xylazine (8 mg/k-g) 
followed by terminal exsanguination. The pancreas was carefully 
excised, rinsed in ice-cold saline and stored in 10% formalin for 
tissue characterization. It was then embedded in paraffin, sectioned 
at 4 µm using a semi-automated microtome and the tissue sections 
mounted on glass slides using a hot plate. After deparaffinization 
with xylene, rehydration with 100%, 90% and 70% dilutions of 
ethanol, the sections were stained with Hematoxylin and Eosin (H 
and E) and the changes in pancreatic tissues observed [46]. 
Stability studies 
Accelerated stability studies were conducted as per ICH Q1C 
guidelines on the optimized formulation to assess the stability with 
respect to physical appearance, drug content and drug release 
characteristics after storing in a stability chamber (Thermolab) at 40 
°C/75% (RH) for 6 mo. The formulation was filled in an HDPE bottle 
with induction sealed CRC caps [47, 48]. 
RESULTS AND DISCUSSION 
Preformulation study 
Drug-excipient compatibility studies by FT-IR 
No significant shifts or reduction in the intensity of the FTIR bands 
of MH were seen. Characteristic shoulders were observed at 1623 
cm-1 for the C=N stretching, 1544 cm-1 for the N-H bending, 1164 cm-
1 for the of the C-N stretch, 3288 cm-1
Metformin HCl liquid oral in situ gel 
 for the N-H stretching 
respectively. These bands were also observed for the physical 
mixture of polymers along with MH, thus confirming that there was 
no interaction between MH, polymers and excipients used and that 
they were compatible with the drug.  
In the prepared formulation, sodium alginate along with pectin were 
used as to modulate and prolong the drug release and the combination 
gave a synergistic effect. HPMC was incorporated as a viscosity enhancer 
in order to achieve the desired consistency so as to facilitate sustained 
release and also reduced the amount of sodium alginate used. Calcium 
carbonate was used as a source of calcium ions, sodium citrate to 
prevent gelation outside the gastric environment and to complex with 
the free calcium ions and release them in the highly acidic environment 
of the stomach. Sorbitol, polyhydroxy alcohol, was used as stabilizing 
agent cum sweetener (it does not increase the blood glucose levels) and 
sodium benzoate as preservative. The formulation remained in the liquid 
form until it reached the stomach where instantaneous gelation 
occurred, thereby sustaining the drug release. The ion activated gel so 
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formed floated on the gastric fluids. The basic mechanism of floating was 
that the calcium carbonate present in the formulation as an insoluble 
dispersion becomes soluble in the acidic medium, releasing Ca2+and CO2 
Design of experiment and ANOVA 
gas, causing gelation of the polymer and the gas released in the 
entrapped gel matrix caused the system to float [49]. The pH of the 
formulations was 6.8-7.2 which was within the acceptable range for 
liquid orals. The carbonation also had a synergistic effect in the taste-
masking (in the pH range of 4 to 9). The viscosity was near or greater 
than 1 (the maximum limit a flowing liquid can have).  
The Two-Square Factorial design was used to discover the vital 
factors in the formulation that influence the various responses, 
including physicochemical properties and drug release. The factors 
used in the formulation, their proportions as per the design and the 
values of the responses are as enlisted in table 1 and the response 
variables of prepared formulations F1-F6 are seen in table 2. Each of 
the readings was performed in triplicate and the average taken. 
 
Table 1: Formulation chart of metformin HCl in situ gel as per fit model design (JMP) 
Formulation code F1 F2 F3 F4 F5 F6 
Metformin Hydrochloride (g) 1 1 1 1 1 1 
Sodium alginate (mg) 125 70 125 70 125 70 
Pectin (mg) 50 50 50 50 50 50 
HPMC 
(mg) 
E50 50 50     
K4M    50 50  
K100M   50   50 
Ultra-Millipore water (ml) 10 10 10 10 10 10 
*All other quantities in the formulation are constant i.e., Sodium citrate 25 mg, Sorbitol 10%, Calcium carbonate100 mg, Sodium benzoate 10 mg 
 
Table 2: Response variables of the prepared formulations F1-F6 
Formula code  pH Gelation time (sec) Floating lag time (sec) Viscosity of sol (cP) Viscosity of gel (cP) Drug content (%) 
F1 7.2 2 75 410 1500 92.35 
F2 7.3 10 110 360 1200 94.26 
F3 7.1 2 150 1010 4240 95.65 
F4 6.9 3 96 380 1620 98.26 
F5 6.8 2 130 490 1840 96.73 
F6 7.1 4 195 920 4110 93.78 
 
The line of fit for the three grades of HPMC in the plot of sodium 
alginate versus % Cumulative drug release at 3h and the correlation 
between the actual and predicted values for %CDR for 3h is seen in 
fig. 1a and 1b. 
 
 
Fig. 1: (a) Line of fit of the different grades of HPMC used for sodium alginate vs %CDR at 3h (b) Predicted vs Actual values 
 
The line of fit showed a linear regression line with confidence intervals 
fixed at 95% confidence for the predicted value (fit). The equations from 
the linear regression analysis for the responses are as follows:  
Gelation time, R1 = 3.833 − 1.833 X1 + 2.166X2a − 1.333X2b −
0.833X2c (Eq 1) 
Floating lag time, R2 = 126 − 7.6666X1 − 33.5X2a − 13X2b + 46.52c 
(Eq 2) 
Viscosity of sol, R3 = 595 + 41.666X1 − 210X2a − 160X2b + 370X2c 
(Eq 3) 
Viscosity of gel, R4 = 2418.333 + 108.333X1 − 1068.333X2a −
688.333X2b + 1756.666X2c (Eq 4)  
%CDR at 1h, R5 = 39.258 − 8.401X1 + 11.306X2a − 2.923X2b −
8.383X2c (Eq 5) 
%CDR at 3h, R6 = 53.661 − 6.641X1 + 3.783X2a − 1.501X2b −
2.281X2c (Eq 6)  
%CDR at 8h, R7 = 90.34 − 3.61X1 − 1.48X2a + 1.11X2b + 0.37X2c (Eq 
7) 
%CDR at 12h, R8 = 98.66 − 0.826X1 − 0.915X2a + 0.61X2b (Eq 8) 
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Where X1 was the sodium alginate concentration and X2a indicated 
HPMC E50 (coded level-1), X2b represented HPMC K4M (coded level 0) 
and X2c represented HPMC K100M (coded level+1) respectively. The 3D 
surface response curve (fig. 2) also showed the relationship between the 
polymer concentrations and drug release at 3h. The regression analysis 
is a statistical tool used to determine the probable change in one variable 
for a given change in another. The magnitude of the change in response 
caused by varying the factor level is denoted as an effect. The main effect 
is the effect of a factor averaged over all the levels of other factors. Such 
data is suitably modelled to generate mathematical relationships 
between the independent and dependent variables. The response 
surface is a graphical depiction of the mathematical relationship [50]. 
Rheological studies 
The formulations were sols at lower pH (indicating ease of 
pourability and swallowing) while they gelled at gastric pH, thus 
improving the gastric residence time and sustaining the release. The 
viscosity of the sols varied from 360 to 1010 cps while that of the gel 
varied from 1200 to 4240 cps on changing the rpm from 10 to 50 (at 
37 °C). The hydrogels exhibited pseudoplastic rheology, the value of 
the flow index (n) being less than 1. Smaller the flow index values, 
more marked is the shear thinning. By knowing rheological 
properties, the composition can be modulated, designing hydrogels 




Fig. 2: 3-D surface response graph for 3h drug release 
 
For the above-mentioned responses, the probability value was found 
to be significant (i.e., *p<0.05) for viscosity of the sol and gel as well 
as drug release at 12h (table 3).  
Thus, the ANOVA established the statistical significance of the two 
factors in formulating a liquid oral sustained release formulation of 
MH. 
 
Table 3: Summary of ANOVA for significant responses as per least square fit model 
Source Sum of squares DF F ratio p-value Prob>F 










































































 (*p value significant i.e.,<0.05) 
 
Table 4: Effective summary as per least-square fit model (JMP) 
Source Log worth   Value 
Sodium alginate (0.7,1.25) 2.908  0.00124  (significant) 
HPMC 0.5% 2.647  0.00225 (significant) 
The logworth values as seen in table 4 are also a good statistic for plotting and assessing significance. A log worth value exceeding 2 indicates that 
the effects are significant at 0.01 level. 
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In vitro gelation, floating and drug release studies 
The nature of floating was as seen in fig. 3. The formulation 




Fig. 3: (a) Liquid oral (b) Ionic gelation of the liquid oral on contact with SGF, (c) Floating in situ gel 
 
 
Fig. 4: In vitro dissolution profiles of the drug from the prepared formulations F1-F6 *Each reading was determined in triplicate (n=3), 
average taken, data given as mean±SEM) 
 
The in vitro drug release studies for the formulations were done and 
the results compared (fig. 4). The formulation F5 showed maximum 
sustained drug release. The drug release data fitted into the various 
models showed very close r2 values (above 0.8). The r2
For each of the responses (Yi), the desirability function D (Yi) 
assigned values ranging from a completely undesirable value of 0 to 
a completely desirable response of 1. The optimized formulation was 
prepared according to Prediction profiler (fig. 5) and evaluation is 
done. Profiling is an approach to visualize response surfaces (cross-
sectional view) by seeing what could happen if one or two factors 
are changed at a time. Interactive profilers help in exploring 
opportunity spaces. There was a good relationship between the 
experimented and predicted values, which confirmed the 
practicability and validity of the model. 
 values of the 
Higuchi model of all the formulations showed higher values 
indicating that the drug release was directly proportional to square 
root of time. But n values ranging from 0.2033 to 0.5239 indicated 
Fickian diffusion mechanism. It may be coincident. However, n 
values of Korsmeyer-Peppas strongly indicated Fickian diffusion 
mechanism. 
Statistical optimization 
The in vitro drug release of the optimized formulation and marketed 
product were compared (table 5) and the similarity factor was found 
to be 75.404. The marketed product released the drug at the 
minimum limit (25%) while the optimized product released the drug 
towards the average value of the official limit (37.98%) and has been 
graphically represented as seen in fig. 6. 
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Fig. 5: Statistical optimization done using prediction profiler 
 
Table 5: Drug release profile of optimized formula and comparison with marketed SR product of metformin hydrochloride 
Time (h) %CDR (Optimized formula) %CDR (Marketed product) IP specifications 
1 37.986 25.593 Not less than 25% and not more than 50% in 1h 
2 48.076 31.746 
3 61.669 45.12 Not less than 45% and not more than 75% in 3h 
Not less than 80% in 8h 4 69.463 53.090 
5 73.496 62.526 
6 75.983 72.506 
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Fig. 6: Comparison of dissolution profiles for marketed product and optimized formulation. (Readings were taken in triplicate (n=3) and 
averaged (data given as mean±SD) 
 
 
Fig. 7: In vivo pharmacodynamic study showing reduction in blood glucose level following oral administration of MH solution and the in-
situ gel in streptozotocin induced diabetic rabbits (n=6, data given as mean±SEM) 
 
Pharmacodynamic study 
The results of the pharmacodynamic study indicated that the 
optimized formulation showed a reduction in blood glucose levels in 
the Wistar rats (fig. 7). 
Also, prolonged release of the MH in situ gel has been observed due 
to the persistence of drug in the body [52]. 
Histological safety evaluation 
The light microphotographs of pancreatic tissue samples 
(Hematoxylin and Eosin stained, 40x) of the normal control as seen 
in fig. 8 showed (a) normal architecture of the islets of Langerhans 
and these were interspersed in between the acinar cells. The blood 
vessels and pancreatic tissue were also intact without any red 
swelling or inflammatory infiltration in the control group. However, 
the diabetic control group (b) showed pathological changes in both 
the exocrine and endocrine components. The acinar cells were 
swollen and small vacuoles were seen in almost all the cells. The β 
cells of the islet of Langerhans were almost entirely destroyed in the 
STZ treated group as seen in the fig. 8b where no islets are visible. In 
the group treated with MH solution (c) there was slight distortion in 
the architecture while in the optimized formulation i.e. MH in situ 
gel treated group (d), the endocrine portion of pancreas indicated 
less severe atrophic changes in the acinar cells and the border 
between the endocrine and exocrine portions were more distinct. 
Normal architecture of exocrine glands with columnar epithelial 
cells with a basal nucleus and pink staining secretions was observed 
with no degeneration islets of Langerhans cells. In fact, the 
replenishment of insulin-producing pancreatic β cells was observed 
due to this optimized, controlled release formulation of MH in situ 
gel which is crucial in treating diabetes and its complications thus 
overcoming inadequacies of the current treatment strategies. 
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Fig. 8: Light microphotographs of (a) control mice showing normal pancreas b) diabetic mice with streptozotocin-induced diabetic 
pancreas showing degenerative, necrotic changes and disappearance of the β-cells c) diabetic mice treated with Metformin solution 
showing reappearance of the β-cells d) diabetic mice treated with optimized MH in situ gel showing marked improvement with 
regeneration of β cells of the islets of Langerhans) (*n=6, all values expressed as mean±SD) 
 
These results are in agreement with previous studies done [53] which 
have confirmed that there is a progressive deterioration in β-cell 
function and mass in Type 2 diabetes. The islet function declined to 50%, 
at the time of diagnosis and a reduction in β-cell mass of about 60% was 
shown at necropsy, the latter being attributable to accelerated apoptosis. 
Impaired β-cell function and possibly β-cell mass appear to be reversible, 
particularly at early stages of the disease. Interventions to preserve or 
rejuvenate β-cells can thus help improve the function of these cells [54]. 
Thus, histopathological studies have confirmed that the administration 
of the optimized SR formulation of MH in situ gel could again increase 
the number and size of the islet cells. 
Stability studies 
Stability studies carried out on the optimized formulation as per ICH 
guidelines (Q1C) revealed no significant changes in the 
physicochemical properties, gelling capacity or drug release of the 
formulation even on the aging of the in-situ gel under the different 
storage conditions. Also, shelf life of up to 2 y was observed. 
CONCLUSION 
It can be concluded that a promising, stable sustained release, liquid oral 
floating in situ gelling systems of Metformin Hydrochloride that met the 
official specifications of sustained drug release could be successfully 
developed using Statistical design and optimization techniques. 
Therapeutic concentrations of the drug could be achieved in plasma in a 
controlled manner and the drug release was sustained for 12h when 
compared to the conventional dosage forms (tablets). The formulation 
also helped in the regeneration of the β cells of the islets of Langerhans. 
Incorporation of large doses of drug would be possible with such liquid 
oral formulations and the simple, economic method of formulation 
indicate the feasibility and ease of production on a larger scale. 
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